Novartis
Novartis is a dominant force in the gene and cell therapy market, primarily through its Novartis Gene Therapies division, which originated from the acquisition of AveXis. The company pioneered the field with the launch of Zolgensma (onasemnogene abeparvovec-xioi), one of the first gene therapies approved globally for spinal muscular atrophy (SMA). Additionally, Novartis is a leader in oncology cell therapy, having developed Kymriah (tisagenlecleucel), a foundational CAR-T therapy for certain blood cancers. Its extensive portfolio is underpinned by continuous strategic investment, including the acquisition of companies like Gyroscope Therapeutics to expand its gene therapy presence into ophthalmology, such as treatments for geographic atrophy. The company focuses on developing robust pipelines across rare genetic diseases and oncology, leveraging its global scale and deep expertise in biologics manufacturing and clinical development to deliver transformative, one-time treatments to patients worldwide.
Latest Market Research Report on Gene Therapy Download PDF Brochure Now
Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb is a major global biopharma company with a significant, high-growth footprint in cell and gene therapy, particularly in the oncology sector. Through strategic acquisitions, including Celgene and Juno Therapeutics, BMS has established one of the industry’s leading autologous CAR-T cell therapy franchises. The company has secured multiple FDA approvals for its cell therapy products, notably Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel), which are vital treatments for multiple myeloma and certain types of large B-cell lymphoma, respectively. BMS continues to invest heavily in its pipeline, focusing on next-generation cell therapies and proprietary platforms to address a wider range of solid and hematological tumors. Its extensive R&D capabilities and commercial infrastructure position it as a key driver in making personalized, innovative cell and gene therapies a standard of care for patients with high unmet medical needs globally.
Gilead Sciences / Kite Pharma
Gilead Sciences, through its wholly-owned subsidiary Kite Pharma, is a preeminent leader in the field of CAR-T cell immunotherapy for oncology. Kite is distinguished by its commercial success and market leadership in developing and delivering transformative cell therapies. Their flagship products, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), are established, FDA-approved treatments for various forms of aggressive non-Hodgkin lymphoma and mantle cell lymphoma. Kite’s focus is on engineering a patient’s own T-cells (autologous cell therapy) to specifically target and destroy cancer cells. The company maintains robust manufacturing capabilities and a specialized supply chain to ensure the rapid and reliable production of these complex, personalized treatments. With a continuous commitment to expanding product labels, improving CAR-T technology, and accelerating access, the Gilead/Kite partnership remains a critical innovator in the global cell and gene therapy landscape.
CRISPR Therapeutics
CRISPR Therapeutics is a pioneering gene-editing company that has fundamentally reshaped the cell and gene therapy industry. The company is built upon the revolutionary CRISPR/Cas9 platform, which allows for highly precise and targeted editing of the human genome to treat serious diseases. In partnership with Vertex Pharmaceuticals, CRISPR Therapeutics achieved a historic milestone with the FDA approval of Casgevy (exagamglogene autotemcel), the first-ever CRISPR-based gene therapy, indicated for sickle cell disease and beta-thalassemia. Beyond this landmark product, the company maintains a deep and promising pipeline, including both *ex vivo* (cells edited outside the body) and *in vivo* (editing within the body) candidates for oncology, cardiovascular disease, and other genetic disorders. Its foundational IP and ongoing clinical advancements confirm its position as a disruptive and influential force at the cutting edge of gene therapy.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a major biotechnology company recognized for its leadership in developing therapies for cystic fibrosis, and it has successfully leveraged strategic collaborations to become a key player in the gene therapy space. Vertex partnered with CRISPR Therapeutics on the development and commercialization of Casgevy (exagamglogene autotemcel), the breakthrough CRISPR-based therapy approved for sickle cell disease and beta-thalassemia. This landmark approval solidifies Vertex’s commitment to gene editing as a core therapeutic modality. The company is actively establishing collaborations and expanding its internal capabilities to develop new genetic medicines for serious diseases. Vertex’s strong commercial foundation, coupled with its gene-editing partnerships, provides the resources and expertise necessary to translate innovative gene therapy research into commercial products with transformative potential for patients.
Genetix Biotherapeutics (formerly bluebird bio)
Genetix Biotherapeutics, formerly known as bluebird bio, is a company focused on developing gene therapies for severe genetic diseases, particularly hematological disorders. The company has successfully navigated complex commercial and regulatory pathways, resulting in the approval of three gene therapy products: Zynteglo (betibeglogene autotemcel) for beta-thalassemia, Skysona (elivaldogene autotemcel) for cerebral adrenoleukodystrophy (CALD), and Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease (SCD). These approvals, achieved using lentiviral vector platforms, make the company a unique leader in the number of approved gene therapies. Despite market access challenges, its approved products demonstrate its core competence in *ex vivo* hematopoietic stem cell gene therapy, positioning Genetix Biotherapeutics as a primary source for transformative treatments for patients with rare, life-threatening monogenic diseases.
Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biotechnology company that specializes in developing RNA-targeted and gene therapies for rare neuromuscular diseases. Sarepta is particularly prominent for its work in Duchenne muscular dystrophy (DMD), where its gene therapy, Elevidys (delandistrogene moxeparvovec-rokl), was approved as a landmark treatment. The company’s focus is on harnessing various genetic medicine modalities, including gene therapies using adeno-associated virus (AAV) vectors, to deliver genetic material that enables the body to produce essential, missing, or non-functional proteins. Sarepta’s robust pipeline and proprietary platform technologies are dedicated to addressing a wide array of neuromuscular conditions, such as limb-girdle muscular dystrophies and other CNS disorders, affirming its role as a key innovator in developing treatments for diseases with high unmet need.
Roche
Roche is a global healthcare giant with a major and integrated presence in the cell and gene therapy field, primarily through its diagnostics and pharmaceutical divisions. Roche significantly bolstered its position by acquiring Spark Therapeutics, a pioneer in gene therapy responsible for Luxturna (voretigene neparvovec-rzyl), a gene therapy for an inherited retinal disease. The company’s strategy involves both internal R&D and strategic acquisitions to build a robust and globally distributed gene therapy pipeline. Roche’s therapeutic focus spans ophthalmology and a range of other conditions, including inherited retinal diseases. Its comprehensive capabilities encompass the entire development process, from cell isolation and vector manufacturing to quality control and global commercialization, ensuring that innovative cell and gene therapy solutions are integrated into its broad portfolio of advanced diagnostic and therapeutic products.
Pfizer
Pfizer is a multinational pharmaceutical corporation that has made significant, strategic investments to become a key player in gene therapy. The company has secured FDA approval for Beqvez (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B. Pfizer’s approach to gene therapy involves developing and commercializing AAV vector-based treatments for various conditions, including hemophilia and Duchenne muscular dystrophy (DMD). It utilizes a robust research and development pipeline, often through partnerships, to explore and advance new gene therapies. Pfizer’s global reach and substantial manufacturing capacity are critical assets in ensuring the scalable production and distribution of these complex biological medicines, solidifying its commitment to expanding its portfolio of next-generation therapeutic solutions.
BioMarin Pharmaceutical
BioMarin Pharmaceutical is a prominent biotech company that is a pioneer in developing therapies for rare genetic diseases, with a strong commitment to gene therapy. The company achieved a major milestone with the approval of Roctavian (valoctocogene roxaparvovec-rvox), a one-time gene therapy indicated for the treatment of severe hemophilia A. Roctavian represents a significant advance by using an AAV vector to introduce a functional gene copy, allowing patients to produce the missing factor VIII protein. BioMarin’s core strategy is focused on leveraging its deep expertise in rare disease biology and its proprietary AAV gene therapy platform to address conditions with limited treatment options. Its long-standing experience in the rare disease space positions it as an authoritative and crucial company in the commercial development and delivery of specialized genetic medicines.
Cellectis
Cellectis is a biotechnology company that is a pioneer and a leader in developing gene-edited allogeneic (off-the-shelf) CAR-T cell therapies for cancer. The company utilizes its proprietary TALEN (Transcription Activator-Like Effector Nuclease) gene-editing technology to engineer T-cells from healthy donors, which can be stored and administered to any eligible patient. This allogeneic approach addresses the major limitations of *autologous* CAR-T therapies—such as complex logistics, manufacturing failures, and long wait times—by creating a more scalable and readily available product. Cellectis’s pipeline focuses on hematological malignancies, aiming to provide a standardized, high-quality, and more accessible cell therapy option, securing its position at the forefront of genome engineering and the advancement of next-generation immunotherapy.
Beam Therapeutics
Beam Therapeutics is a leading innovator in the gene therapy space, distinguished by its focus on base editing, a next-generation form of gene editing technology. Unlike traditional CRISPR/Cas9, which cuts both strands of DNA, base editing allows for the precise chemical conversion of a single DNA base pair into another without causing a double-strand break. This method is believed to offer a higher degree of precision and control. The company’s lead gene therapy candidate, BEAM-101 for sickle cell disease, has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Beam is applying its base editing platform to develop therapies for a broad range of genetic disorders, making it a critical company to watch for advancements in highly specific, non-destructive genomic manipulation.
Intellia Therapeutics
Intellia Therapeutics is a key player in the gene-editing sector, focused on developing curative therapies using its proprietary CRISPR/Cas9 technology. The company is a pioneer in the challenging and high-potential field of *in vivo* gene editing, where the gene-editing components are delivered directly into the body to edit cells in their natural environment. Intellia achieved a major milestone by running the first-ever systemic *in vivo* CRISPR clinical trial. Its lead candidate, NTLA-2001, is being advanced in collaboration with Regeneron for the treatment of transthyretin amyloidosis (ATTR). By targeting genetic diseases directly at the source, Intellia aims to overcome the complexity of *ex vivo* manipulation and manufacturing, positioning itself as a central force in expanding the reach and application of genetic medicines.
Krystal Biotech, Inc.
Krystal Biotech is a commercial-stage gene therapy company that specializes in developing and commercializing genetic medicines for rare diseases, particularly those affecting the skin. Krystal’s proprietary redosable gene delivery platform is based on a modified herpes simplex virus (HSV) vector designed for topical administration. The company’s landmark achievement is the approval of VYJUVEK (beremagene geperpavec-svdt), a topical gene therapy indicated for the treatment of dystrophic epidermolysis bullosa (DEB), a rare and painful genetic skin disorder. This unique, non-invasive delivery method for a genetic medicine sets Krystal apart in the industry, demonstrating the versatility of gene therapy beyond systemic and cellular applications. Krystal’s focus on rare skin and potentially other epithelial diseases makes it a specialized and vital contributor to the gene therapy market.
Adaptimmune Therapeutics
Adaptimmune Therapeutics is a clinical-stage biotechnology company that has established itself as a leader in developing engineered T-cell therapies for the treatment of solid tumors. The company’s proprietary platform is based on engineered T-Cell Receptors (TCRs) that enable a patient’s T-cells to specifically recognize and target cancer cells expressing particular tumor-associated antigens, such as MAGE-A4. Adaptimmune achieved a significant breakthrough with the accelerated FDA approval of Tecelra (afamitresgene autoleucel), the first-ever approved engineered cell therapy for a solid tumor—advanced synovial sarcoma. Its focus on solid tumors, a more challenging area for cell therapies than hematological cancers, demonstrates its platform’s unique power. Adaptimmune’s continuous efforts in improving TCR-T cell affinity and targeting are driving its pipeline advancements in various cancers.
Autolus Therapeutics
Autolus Therapeutics is a clinical-stage oncology company dedicated to developing next-generation autologous CAR-T cell therapies. Autolus is focused on creating therapies with enhanced functionality and safety profiles to improve treatment outcomes for patients with cancer and autoimmune diseases. The company’s modular and advanced CAR-T platform allows for the engineering of T-cells with novel features, such as those that can resist checkpoint inhibition or target multiple antigens. Autolus recently secured FDA approval for Aucatzyl (obecabtagene autoleucel), indicated for adult B-cell acute lymphoblastic leukemia. This approval and the promising clinical data supporting it solidify Autolus’s position as a key innovator in the crowded CAR-T landscape, working to expand the efficacy and accessibility of cell-based immunotherapies.
Regeneron
Regeneron is a major biotechnology company that is expanding its therapeutic reach through strategic investments and collaborations in the cell and gene therapy sector. The company has built an internal pipeline featuring multiple clinical-stage cell and gene therapies, targeting a range of conditions including ocular, muscular, and neurological diseases. A key component of its strategy is a significant collaboration with Intellia Therapeutics, focusing on the co-development of CRISPR-based therapies, including the *in vivo* gene editing candidate NTLA-2001 for transthyretin amyloidosis. Regeneron leverages its deep expertise in antibody development and genetics-based drug discovery to identify and advance gene therapy targets, positioning it as a powerful collaborator and developer in the field, aiming to translate fundamental genetic insights into effective new treatments.
Abeona Therapeutics
Abeona Therapeutics is a clinical-stage biotechnology company dedicated to developing gene and cell therapies for rare genetic disorders, focusing particularly on diseases with high unmet medical needs. The company utilizes adeno-associated virus (AAV) vector platform technologies to deliver therapeutic genes, with pipeline candidates aimed at conditions like Infantile Batten Disease, Rett Syndrome, and Sanfilippo Syndrome Type A. Abeona recently received a Biologics License Application (BLA) from the US FDA for pz-cel, a gene therapy in development to treat recessive dystrophic epidermolysis bullosa (RDEB). This focus on rare, often devastating monogenic diseases, combined with its strong regulatory progress and pipeline diversity, establishes Abeona as a determined and specialized player in advancing genetic medicines for patient populations with limited or no current treatment options.
Rocket Pharmaceuticals
Rocket Pharmaceuticals is a clinical-stage biotechnology company singularly focused on developing first-in-class gene therapies for rare and devastating pediatric diseases. The company’s platform utilizes both *ex vivo* lentiviral vector-based gene therapy for blood disorders, and *in vivo* AAV-based gene therapy for heart disease. Rocket’s pipeline includes candidates for conditions such as Danon disease and various forms of Leukocyte Adhesion Deficiency (LAD-I). The company’s commitment to advancing treatments for very young patients is evidenced by its engagement with regulatory bodies, including the resubmission of a Biologics License Application for KRESLADI for severe LAD-I. This specialized and patient-focused approach underscores Rocket’s mission to deliver permanent, single-dose cures for children suffering from life-threatening genetic disorders.
4D Molecular Therapeutics (4DMT)
4D Molecular Therapeutics is a clinical-stage gene therapy company that distinguishes itself through the development of proprietary, customized adeno-associated virus (AAV) vectors. The company uses its therapeutic vector evolution platform, AAVant-garde, to design vectors optimized for specific disease targets, routes of administration, and cell types. This engineering focus is intended to create superior delivery vehicles that can improve therapeutic efficacy and safety. 4DMT’s pipeline includes treatments for ocular diseases, such as the lead candidate 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema. By concentrating on vector design as a core competency, 4DMT addresses one of the fundamental challenges in gene therapy—efficient and safe delivery—securing its role as a key technical innovator in the broader genetic medicine landscape.
Latest Market Research Report on Gene Therapy Download PDF Brochure Now